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1. Abbreviations 
ANA: Antinuclear Antibodies 
BO: Bacterial Osteomyelitis  
CARRA: Childhood Arthritis and Rheumatology Research Alliance 
CNO: Chronic Nonbacterial Osteitis 
CRMO: Chronic Recurrent Multifocal Osteomyelitis 
CRP: C-Reactive Protein 
CT: Computed Tomography 
ESR: Erythrocyte Sedimentation Rate 
Hib: Haemophilus Influenzae Type B 
HLA: Human Leukocyte Antigen 
IBD: Inflammatory Bowel Disease 
IL: Interleukin 
LPS: Lipopolysaccharide 
MTX: Methotrexate  
MRI: Magnetic Resonance Imaging 
MRSA: Methicillin-Resistant Staphylococcus Aureus 
NBO: Nonbacterial Osteitis 
PCR: Polymerase Chain Reaction  
PPP: Palmoplantare Pustulosis 
RANK: Receptor Activator of Nuclear Factor-кB 
RANKL: Receptor Activator of Nuclear Factor-кB Ligand  
SAPHO: Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis 
SPSS: Statistical Package for the Social Sciences 
TLR: Toll Like Receptor 
WB-MRI: Whole-Body Magnetic Resonance Imaging 
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4. Introduction 
The term osteomyelitis describes inflammation of the bone and/or bone marrow, which 
compromises the cortical bone and periosteum and is typically microbial triggered [1, 2]. 
However in 1972, Giedion et al. described for the first time a form of bone inflammation which 
appeared to be of a nonbacterial origin and thus, coined the term chronic recurrent multifocal 
osteomyelitis (CRMO) [3]. In subsequent years, the terms nonbacterial osteitis (NBO) and chronic 
nonbacterial osteitis would be added. Osteitis conversely describes not only bone marrow 
inflammation, but inflammation of the bone and surrounding soft tissue [2]. Today the terms 
osteomyelitis and osteitis are often used as synonyms.  
Patients with oncologic diseases, with immune deficiencies, post-injury, or infants are 
predisposed to bacterial osteomyelitis [4]. But in the ever advancing diagnostics and the 
increasing usage of WB-MRIs (whole-body magnet resonance imaging), bone lesions are being 
detected in both pediatric patients as well as adult patients, who otherwise presented and appeared 
healthy [5, 6]. These radiologically confirmed bone lesions closely resemble those of bacterial 
osteomyelitis; however, they seem to be of an autoinflammatory origin [7].  
Physicians are often confronted with patients presenting with bone pain and lesions, 
leading many to assume these manifestations to be of bacterial origin, primarily bacterial 
osteomyelitis, regardless whether an isolated pathogen is found. Therefore, the chief complaint of 
localized bone pain, which is present in both NBO and BO, can be a diagnostic challenge [6, 8, 9].  
The topic of this dissertation and research compared and contrasted nonbacterial osteitis 
and bacterial osteomyelitis (BO) in a study from July 2006 – July 2011 using the German 
Surveillance Unit for Rare Diseases in Childhood (Erhebungseinheit für Seltene Paediatrische 
Erkrankungen in Deutschland (ESPED)). Data was collected in all pediatric hospitals and 
orthopedic departments nation-wide, capturing NBO cases for the whole time period (5 years) 
while bacterial osteomyelitis cases were added from July 2009 onwards (2 years).  
The second portion of this dissertation gathered, analyzed, and evaluated the impact of 
chronic nonbacterial osteitis (CNO) from the patient perspective based on surveys from patient 
conferences held in 2013 and 2015. These questionnaires were developed to include not only the 
symptoms, diagnostics, and treatment plans but also the social impact that the chronically ill face 
as well as access to care issues with which patients are confronted. A primary focus in the survey 
was dedicated to how well the patients were versed in CNO and which difficulties were 
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encountered. Much emphasis was placed on the socio-economic effect along with the 
psychosocial aspects of such a disease.  
Nonbacterial Osteitis General Information 
Nonbacterial osteitis (NBO) is an autoinflammatory bone disease, with or without 
associated diseases, and can be subdivided into an acute form and a chronic form [10]. The 
chronic form can be again allocated further into chronic nonbacterial osteitis (CNO) which 
includes all chronic forms, unifocal and multifocal disease as well as relapsing and persistent 
osteitis, and chronic recurrent multifocal osteomyelitis (CRMO). CRMO usually represents the 
most severe subform of CNO [11-15].  
CRMO is often regarded to be the pediatric equal of the SAPHO syndrome (Synovitis, 
Acne, Pustulosis, Hyperostosis, Osteitis), which is better known in adult health care [16-18], and 
both diseases may include unifocal or multifocal nonpyogenic bone lesions, osteitis, hyperostosis, 
pustulosis, normal body temperature and good general health [10, 15]. CRMO is often 
characterized through spontaneous flares and remissions [19, 20].  
Pathogenesis 
Although the etiology is unknown, recent data, both from patient and mouse models, 
suggest a genetic component for NBO [18, 20-25]. Through a family based association study, 
Jansson et al. were able to demonstrate the roll of genetics in the disease emergence with more 
than one-third of the population’s study expressing a rare allele on Chromosome 18 [21].  
Most current research has also shown in response to toll like receptor (TLR) 4 with 
lipopolysaccharide (LPS) that monocytes from NBO patients fail to express or have reduced 
expression of interleukin 10 (IL-10) and interleukin 19 (IL-19), leading to a significant imbalance 
between pro-inflammatory and anti-inflammatory signals [25-29]. This downregulation of anti-
inflammatory signals, results in increased activity of pro-inflammatory cytokines, especially TNF 
alpha, interleukin 1β (IL-1β), interleukin 6 (IL-6), and interleukin 20 (IL-20) [25, 27, 30]. The 
aforementioned pro-inflammatory cytokines lead to an amplified interaction between RANK 
(receptor activator of nuclear factor-кB) receptors and RANKL (RANK ligand), resulting in 
induced osteoclast differentiation and activation [25, 31], which therefore results in the typical 
osteolytic lesions seen in NBO patients.  
6 
 
Ferguson et al. were able to further demonstrate that the lack of functional interleukin 1β 
(IL-1β) served as a protection factor leading to an attenuated response or complete absence of 
disease [18].  
Epidemiology  
To date there has been only one large national study concerning the incidence rates of 
NBO, which was completed by the Department of Rheumatology and Immunology in Dr. von 
Hauner Children’s Hospital in 2017. The incidence rate in Germany is estimated to be 
0.45/100,000 [9]. In the German-wide study, there was a preponderance of females (64%) in the 
NBO cases and the mean age at time of diagnosis was 11 years old (SD: 3.2 years) [9].    
Girschick et al. recently publicized data from an international registry (Eurofever) 
encompassing 486 patients with NBO, which closely statistically correlates with the national 
NBO study completed in 2017. The study revealed a likewise 64% female majority with a mean 
age at time of diagnosis of 10.9 years [28].  
Symptoms and Clinical Presentation 
While lesions in NBO may appear at any skeletal site and may appear unifocal or 
multifocal, multiple lesions primarily appear in the pelvis, feet, or metaphyseal in the tibia or 
femur [10]. However, lesions in the clavicle, vertebrae, mandible, and sternum are all more 
commonly found in NBO patients in contrast to bacterial osteomyelitis (BO) patients [9, 10, 19].  
The chief complaint centers on localized pain with accompanying tenderness, peripheral swelling, 
and limited range of motion [10, 19]. 
The average course of chronic NBO (CNO) runs approximately 21-29 months, after which 
56% of patients are typically free of complaints [15]. The acute NBO, just like in CNO, is self-
limiting but with a course of disease lasting up to six months [15]. There also seems to be a 
correlation between nonbacterial osteitis and other autoimmune diseases, especially dermatologic 
disorders [32-34]. Palmoplantar pustolosis has been seen in 15-20% of patients with CRMO [35, 
36]. Other cutaneous manifestations such as acne conglobate and acne fulminans [37], pyoderma 
gangrenosum [38], and Sweet’s syndrome [39] have all been associated with sterile multifocal 
osteomyelitis. In a recent study, circa 20% of patients presented with associated diseases 
including but not limited to: chronic inflammatory bowel disease (ulcerative colitis, Crohn’s 
disease, celiac disease), inflammatory bowel disease (IBD), rheumatic disease, psoriasis, severe 
acne and palmoplantar pustulosis (PPP) [11, 15, 40].  
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Diagnostics 
Although no gold standard in the diagnosis for NBO exists, proof of pathogen is usually 
diagnostic for BO; conversely, NBO is a diagnosis of exclusion. However, it must be noted that 
approximately half of NBO patients demonstrate and therefore are subsequently diagnosed with a 
bacterial infection.   
With the omission of the chief complaint of bone pain, NBO patients may be overlooked 
due to an overall good clinical health status. Patients typically present with C-reactive protein 
(CRP) ≥ 1 mg/dl, mildly elevated erythrocyte sedimentation rate (ESR), a normal blood cell count 
and a normal body temperature [9, 13-15, 41, 42]. Fever, localized redness, and lymphadenopathy 
are considered atypical in NBO cases [9, 43]. It has been suggested, based on the above 
mentioned difficulties, that the incidence rate for NBO is much higher than originally thought and 
diagnosed [6, 10].  
Magnet resonant imaging (MRI), bone scintigraphy, and conventional X-ray are the three 
most readily used radiologic diagnostic tools, with MRI and the scintigraphy being the most 
sensitive. In cases with suspected bone destruction, however, MRI is the first choice in 
radiological diagnostics [11, 44]. Radiologic verified bone lesions exhibit marginal sclerosis, and 
in the case of NBO, frequently more than one lesion [6].  Today, the recommendation is a whole-
body MRI (WB-MRI) due to the ever increasing finding of silent lesions [45]. Clinically silent 
lesions but radiologically active lesions require treatment; although, the importance of silent 
lesions is still under discussion [46].  
 In 2007, Jansson et al. proposed “Major and Minor Diagnostic Criteria of NBO”; hence, 
NBO can be diagnosed with either two major criteria or one major plus three minor criteria [15]. 
Presently efforts are being made through CARRA (Childhood Arthritis and Rheumatology 
Research Alliance) in a joint effort with international partners to establish a databank of diagnosis 
criteria based on a large patient population [45, 47].  
In 2013 Jansson et al. further developed a clinical scoring system for how likely a patient 
is to have NBO; this scoring system encompassed blood cell counts, radiology findings (+/- 
osteosclerotic bone lesions), number of bone lesions, symmetry of bone lesions, fever, and CRP 
levels. The scoring ranges between 0-63, and >35 points indicates a case of NBO. Based on the 
resulting score, therapy plans can then be developed [48].  The whole-body MRI plays a 
significant role in this scoring system due to the requirement of finding the total number of lesions 
and the symmetry of said lesions. Without a WB-MRI, most lesions would go unnoticed [46].  
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Another factor to consider in the diagnosis, is histology; however, histology is primarily 
used to distinguish BO from malignancies but not from NBO. The general changes seen in both 
NBO and BO cases are acute and chronic inflammation. Whereas neutrophils largely characterize 
BO cases, NBO is often primarily represented in the histology through lymphocytes and plasma 
cells [44, 49, 50]. Nonetheless, the imbalance of anti-inflammatory and pro-inflammatory 
cytokines resulting from the monocytes significant reduction or failure to produce IL-10 [8, 9, 18] 
could eventually be helpful in developing a laboratory marker for NBO.   
Furthermore HLA-B27 (Human leukocyte antigen B27) was established in 7.9% of 
patients tested, as well as elevated ANA titers in 38% [28]. 
In addition, diseases such as Hepatitis B and C as well as Tuberculosis should be excluded 
before the definitive diagnosis is made and eventually treated. Tuberculosis is especially an 
important differential diagnosis in the case of unifocal lesions [47].  
Therapy 
There are no authorized therapeutic agents for the sole treatment of CNO; therefore, the 
therapy of choice lies with the treating physicians and is considered an “off-line” therapy [47]. 
Additionally there is no established definition for CNO therapy response so far, merely protocols, 
and it is left to the treating physician to classify the response as remission, partial response, or no 
response [28, 45, 47].  
According to many experts in the field, first-line therapy for pediatric NBO patients 
without spinal lesions are NSAIDs (nonsteroidal anti-inflammatory drugs), which have an 80% 
response rate [19, 45, 47, 51]. As escalation therapy, steroids should be considered; although, in 
the case of vertebral fractures, steroid usage should be avoided [19]. If no relief is found with 
NSAIDs or steroids, immunosuppressant drugs (e.g. sulfalazin, methotrexate), TNF-α antagonists 
and bisphosphonates are to be considered, with the latter two being most successful [19, 52-56]. 
Treatment with methotrexate (MTX) and sulfalazin demonstrated lower remission rates and in the 
case of MTX, poor tolerance [54, 55].  
Complementary measures to the pharmaceutical treatment of CNO should also be 
considered. These include but are not limited to physical therapy to help avoid contractures and 
aid in muscle strength, cyro- and thermotherapy for symptomatic relief, orthopedic and medical 
aids for better mobility, vitamin D supplements and psychosocial support [47, 57].  
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A complication of therapy, is the continued use of antibiotics in NBO cases. This 
highlights the uncertainty surrounding the therapy protocol for NBO; therefore, a step-by-step 
guide was developed by Jansson et al. in 2009 to alleviate any ambiguity [52], and in 2018 a treat-
to-target strategy was further developed into a therapy protocol to be used as an interventional 
strategy with flexible application by Schwarz et al. in a joint effort with Childhood Arthritis and 
Rheumatology Research Alliance (CARRA) in North America [45, 47]. Therapy 
recommendations have been standardized recently (2018) in the form of the aforesaid therapy 
protocols both on a national and international level [45, 47].  
Recommended follow-up and if needed, escalation therapy or treatment modification, is 
recommended at the three month assessment appointment. The treatment duration is 
recommended as a minimum of 12 months to achieve the best results and avoid later 
complications [45].  
Complications 
Approximately 20% of patients do not respond well to initial therapy and/or have multiple 
relapses. Furthermore they can develop therapy resistance, osseous changes, vertebral fractures, 
hyperostosis, scoliosis and kyphosis. These complications highlight the urgent need for timely and 
effective therapy [14, 19, 42].  In an orthopedic follow-up study of CNO in Melbourne, Australia 
5/12 patients showed a leg-length discrepancy of  ≥1.5 cm (mean = 3.2 cm), and 50% of these 
patients showed a difference in muscle girth varying between 1.5 cm and 4 cm [58].  
Because NBO is typically chronic, the psychosocial aspect of chronic nonbacterial osteitis 
(CNO) plays a large role in the day-to-day lives of patients. The burden of disease often impairs 
familial relationships and friendships [9, 59]. Therefore, it is important for the physician as well as 
for the patient’s support structure to educate and empower the patient to prevent negative long-
term effects.  
Bacterial Osteomyelitis General Information 
In practice, bacterial osteomyelitis (BO) is the most common differential diagnosis to 
NBO, and until 1972, assumed to be the only form of osteomyelitis [3]. Bacterial osteomyelitis 
can be classified in to three categories: primary acute hematogenous osteomyelitis, secondary 
osteomyelitis through trauma or surgical intervention, and secondary osteomyelitis through 
vascular insufficiency [19]. In children, the primary acute form is by far the most prevalent, 
approximately 90% [19, 60, 61]. Generally in pediatrics the long bones of the lower extremities, 
especially the metaphyses of the femur and the tibia, are most frequently affected [9, 21, 62].  
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Pathogenesis 
Based on the duration of symptoms, BO can be categorized into: acute with a duration 
under two weeks, sub-acute with a duration of two weeks to three months, and chronic with a 
duration longer than three months [4, 63]. The most common pathogen of bacterial osteomyelitis 
is dependent on age, susceptibility factors of the host, and microbial etiology. Newborns are most 
commonly infected with Streptococcus agalactiae and Escheria coli; whereas, in school-aged 
children Staphylococcus aureus, Streptococcus pyogenes and Haemophilus influenza are 
predominantly found. Haemophilus influenza Type B (HiB) is not as prevalent as in the past due 
the increasing number of HiB immunizations [64].  
Kingella kingae is also taking on an ever increasing role in children, especially under four 
years old [4, 65-67]; however, this pathogen is difficult to identify in blood cultures and bodily 
fluid cultures (e.g. synovial fluid) [68]. Evidence suggests that with real-time polymerase chain 
reaction (PCR), the proof of pathogen yield is much higher for K. kingea [67-69]; nonetheless, it 
is not common practice for most practitioners to use PCR without K. kingea suspicion.   
Staphylococcus aureus, the most typical causative pathogen responsible for not only the 
acute form but also for the chronic osteomyelitis, forms a biofilm. This can lead to antimicrobial 
resistance and the further expression of virulence factors [70]. Many multiple resistant strains, not 
only found in a hospital setting, but also community-acquired strains, may result in a delay in 
therapy which increases the risk of disease chronification. The prevalence of methicillin resistant 
staphylococcus aureus (MRSA) and K. kingae vary significantly from location to location [4, 62].  
Epidemiology  
The incidence rate for osteomyelitis has shown large variations. In 2008 in Norway, the 
incidence rate was estimated to be 13/100,000 [71] and in Belgium in 2005 1/5,000[60]. Based on 
a study from 2009 to 2011 in Germany, the bacterial osteomyelitis incidence rate is estimated to 
be 1.2 (-5)/100,000 [9]. The average age at diagnosis in BO cases is 6.6 years old [72, 73], with 
50% of cases occurring in children under five years old [74, 75] and one-third of patients being 
under 24 months old [75]. Males are more often afflicted than females at a ratio of 2:1[74-76].  
Symptoms and Clinical Presentation 
The symptoms of osteomyelitis vary and are dependent upon the age of the child, 
localization of the infection, the virulence of the pathogen as well as the bodily defenses of the 
organism. The beginning is often accompanied with sudden onset of bone pain and fever [60, 74]. 
Children exhibit declining range of motion in the affected bone/extremity so that limited mobility 
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or pseudoparalysis appears [77]. In the case of the lower extremities, a limp may accompany the 
localized pain, swelling, warmth and redness, which may or may not be present as well [61, 74]. 
Newborns are more likely to show restlessness and a refusal to drink or eat [19, 74].  
Diagnostics 
Blood cultures in 20 - 40% of the cases and biopsies in 60% of the cases can help specify 
the causative agent [11, 20, 60, 65, 78]. Biopsy indications include but are not limited to: unifocal 
lesions, B symptoms, and unclear findings [52]. Frequently the decision for further diagnostic 
measures are unspecific. In 85% of cases a leukocytosis is present, in 70% an elevated erythrocyte 
sedimentation rate (ESR), and in 42% is the C-reactive protein (CRP) elevated [60, 79].  
A conventional X-ray can in 85% of cases validate an osteomyelitis; however, osseous 
changes are usually not recognized until two to three weeks after the beginning of disease activity 
[19]. BO tends to present as a unifocal lesion; however, in the case of newborns, BO can and 
often does present multifocal [77, 80]. The first changes to be seen in radiology are soft tissue 
swelling, thickening of the periosteum and a sub-periosteum fluid retention. In the later stages, 
bone density is affected and bone destruction is evident [19]. 
A bone scintigraphy with technetium-99m also helps endorse the suspicion of an 
osteomyelitis, especially in the early stages when the disease is active in other areas of the body 
outside of the long bones. Computed tomography (CT) demonstrates the bone destruction, but the 
magnet resonance imaging (MRI) is still the first choice in diagnostic imaging for bacterial 
osteomyelitis due to the radiation exposure in pediatric patients [19].  
Therapy 
All empiric therapies must take into account the local prevalence of organisms, local 
antimicrobial sensitivities, and underlying conditions. A penicillinase resistant penicillin or 
cephalosporin (cefuroxime) are the two most recommended antibiotics in pediatric osteomyelitis. 
But due to the rising cases of MRSA, clindamycin and vancomycin have been added [62, 81]. 
Some have suggested that new regimens should include MRSA coverage if more than 10% of the 
S. aureus cases are in fact methicillin resistant [62, 78], and Peltola et al. recommended that 
therapy be guided by CRP and ESR levels [82]. Due to the ever rising resistance in the K. kingae, 
caution should be used when administering clindamycin [62].  
Traditionally, acute osteomyelitis was treated four to six weeks long with broad spectrum 
antibiotics [83-85]. New research suggests in children older than three months of age that three to 
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four days of parenteral antibiotics and then transitioning to oral antibiotics for three weeks is as 
effective as a lengthy antibiotic regimen. The recommendation for neonates remains unchanged 
with antibiotics given exclusively parenterally for four weeks [62].  
Complications 
With adequate and timely antibiotic therapy, the risk of BO developing into a chronic 
bacterial osteomyelitis drops dramatically. BO leads to permanent damage in 6 -50% of the cases 
in newborns including lack of growth, leg length discrepancies, arthritis, fractures, and gait 
abnormalities [19]. If the disease cannot be treated appropriately with antibiotics and results in 
chronic bacterial osteomyelitis, the therapy recommendation is radical surgical debridement down 
to living bone [4, 70]. Therefore, being able to better differentiate between NBO and BO should 
help patients and physicians alike to refrain from delay of diagnosis, over treatment, and 
unnecessary treatment.  
Study I 
Beginning in July 2006 through July 2011 using German Surveillance Unit for Rare 
Diseases in Childhood (Erhebungseinheit für Seltene Paediatrische Erkrankungen in Deutschland 
(ESPED)) treating physicians in pediatric hospitals and pediatric orthopedic departments were 
asked to report newly diagnosed NBO cases and later BO cases. NBO cases were defined as 
children >18 months and <18 years of age with newly diagnosed NBO. BO cases were later added 
in July 2009, so that a total study period of two years was achieved. The treating physicians in the 
corresponding hospitals and wards were asked to fill in the detailed clinical information on a 
corresponding report card with the assistance of ESPED representatives at each site.  
At the beginning of the study, each ESPED representative was provided with information 
about nonbacterial osteitis, to include a case definition. The study was also announced in the 
German Pediatric Society’s board journal. The journal additionally provided a timely review 
article on this issue which was linked to the surveillance to assist in the collection of data. 
All centers were asked to report children >18 months and <18 years of age who had been 
in the previous month newly diagnosed with NBO, CRMO, CNO, SAPHO syndrome, bacterial 
osteomyelitis or other inflammatory bone lesions. The primary diagnosis of nonbacterial osteitis 
or bacterial osteomyelitis was made by the treating physician. Children with previous chronic 
illnesses, trauma, surgery, and immunosuppression were excluded from the study, and no 
distinction was made between inpatients and outpatients. The children recruited for the study had 
to have at least one X-ray- or MRI-verified osteolytic/sclerotic or osteosclerotic bone lesion.  
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Each report contained a detailed, two-page report filled in by the treating physicians. After 
the addition of the bacterial osteomyelitis cases in July 2009, minimal changes were introduced to 
the questionnaire. Every form contained the following information: 
Category Details 
General Information Gender, birth date, age at diagnosis, age at onset, associated 
diseases 
Clinical Presentation Including associated symptoms: fever, weight loss, lack of appetite, 
enlarged lymph nodes 
Laboratory Values blood count anomalies, leukocytosis with or without left shift, CRP, 
ESR, ANA titers 
Radiology Findings Scintigraphy, X-ray, MRI, CT with documentation of the number of 
lesions 
Localization of Bone 
Lesions 
Symmetry? Specific localization 
Microbiology Results Bacterial pathogen? 
Therapy Before and after the diagnosis 
Complications  i.e. hyperostosis, vertebrae fractures, vertebra plana, scoliosis, etc. 
 
Good clinical condition was defined as absence of fever, absence of enlarged lymph 
nodes, absence of weight loss and a healthy appetite. CRP > 1 mg/dl, ESR >15 mm/h and ANA 
titers >1:80 were considered to be elevated.  
The collected data was analyzed using Statistical Package for the Social Sciences (SPSS). 
The study highlighted the difficulties in differentiating between NBO and BO and led to the 
conclusion that NBO could be significantly underdiagnosed. This study further defined the 
clinical presentation and confirmed the epidemiological data regarding both diseases. The most 
effective therapies were further investigated as well.  
Study II 
The Pediatric Rheumatology department of the Ludwig-Maximilians-University (LMU) 
Munich hosted CNO patient conferences in June 2013 and again in June 2015. The intended 
audience was to encompass not only the pediatric patients, but adult patients and relatives of 
patients as well. Once registration was completed, patients received a twelve page questionnaire, 
which was to be turned in at the aforementioned conference. From the 134 patients in attendance, 
107 completed the survey and were hence collected (2013: 69 and 2015: 38).  
The patient survey captured 285 variables per patient and focused on important aspects of 
nonbacterial osteitis to include but not limited to: 
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Category Details 
General Information Age at onset and diagnosis, , past medical and treatment history, 
family history and associated disease in patients and family members 
CNO Symptoms and 
Diagnostics 
Symptoms at onset and at time of survey, diagnostic procedures used, 
total number of lesions 
Patient and Family 
Satisfaction 
With consulting physician, treatment plan, treatment options, 
explanation of disease 
Psychosocial Impact On patient, friends, and family 
Absences Due to 
Disease 
At school, work, social functions 
 The data was analyzed using SPSS helping to highlight areas for improvement, such as the 
need for international standardized diagnostic procedures, better transition of care models, and 
enhanced psychosocial and socio-economical support. The conclusion of this study furthermore 
validated the medical literature concerning CNO regarding initial symptoms, clinical presentation, 
and the most effective therapy plans.  
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5. Summary 
The diagnosis of nonbacterial osteitis (NBO) is gaining ground not only in the pediatric 
community but in adult health care as well. The topic of the dissertation presented, firstly aimed to 
compare and contrast nonbacterial osteitis and bacterial osteomyelitis (BO). The second portion 
gathered, analyzed and evaluated the impact of chronic nonbacterial osteitis from the patient 
perspective based on questionnaires from patient conferences.  
Nonbacterial osteitis is an aseptic, autoinflammatory bone disorder, which can present at 
all ages and in all skeletal sites [10]. It can present as acute, chronic persistent, or chronic 
recurrent as well as unifocal or multifocal. NBO is most often known by its most severe form: 
chronic recurrent multifocal osteomyelitis (CRMO) [11-15]. The most common differential 
diagnoses are bacterial osteomyelitis and malignancies (Ewing-sarcoma, osteosarcoma, leukemia, 
histiocytosis) [13, 52].  
The chief complaint of patients is localized bone pain in both NBO and BO, which can 
lead to a diagnostic challenge [19, 86]. However, NBO patients tend be female with a median age 
of 11 years (SD: 3.2 years) and present typically in general good health with multifocal bone 
lesions. In contrast, BO patients tend to be male, younger, and present with unifocal lesions, fever, 
high inflammation markers, and localized redness.  
Whereas proof of pathogen is usually diagnostic for BO, bacterial infections can be 
verified in only half of the patients; conversely, NBO is a diagnosis of exclusion. While a gold 
standard for the diagnosis of NBO does not yet exist, the goal of the first portion of this 
dissertation (ESPED study) was to better differentiate between NBO and BO and to prevent 
unnecessary antibiotic treatments. Timely diagnoses and targeted therapy reduce patient stress and 
reduce the burden on the German healthcare system.  This study was the first prospective 
German-wide study concerning the first manifestation of NBO in childhood and the first 
prospective German-wide study concerning first manifestation of BO in childhood. Through a 
five-year national study, 279 NBO patient data were collected, and in the last 2 years of the study, 
378 BO patient data were additionally collected -leading to the largest study of NBO patients up 
until this point in time.  
The goal of study number two was to gain a better understanding of chronic nonbacterial 
osteitis (CNO) from the patient perspective. Thereby it was important to investigate how well the 
patients were informed regarding CNO, the psychosocial impact was explored, and the approach 
to betterment of treatment and patient care was discussed. Through two patient conferences (2013 
16 
 
and 2015) a total of 107 patients attended and provided us with reliable data through our surveys. 
This data lead to the first study world-wide concerning the impact of chronic nonbacterial osteitis 
from the patient perspective.  
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6. Zusammenfassung 
Die Diagnose nichtbakterielle Osteitis (NBO) wird  zunehmend nicht nur in der Pädiatrie, 
sondern auch in der Erwachsenenmedizin gestellt. Das Thema der vorliegenden Dissertation 
beinhaltet erstmals den Vergleich von nichtbakterieller Osteitis und ihrer häufigsten 
Differenzialdiagnose, der bakteriellen Osteomyelitis (BO). Im zweiten Teil wurden mithilfe von 
Erhebung durch Fragebögen im Rahmen von Patiententagungen die Auswirkungen der 
chronischen nichtbakteriellen Osteitis aus der Patientenperspektive gesammelt, analysiert sowie 
evaluiert.  
Die nichtbakterielle Osteitis ist eine aseptische, autoinflammatorische 
Knochenentzündung, die in jedem Alter und an jeder Lokalisation auftreten kann [10]. Dabei 
kann sie sich unifokal oder multifokal präsentieren sowie akute, chronisch persistierende und 
chronisch rekurrierende Formen ausbilden. Die NBO ist am besten bekannt durch ihre schwerste 
Verlaufsform, die chronisch-rezidivierende multifokale Osteomyelitis (CRMO) [11-15]. Die 
häufigsten Differenzialdiagnosen stellen bakterielle Osteomyelitis und Malignome (Ewing-
Sarkom, Osteosarkom, Leukämie, Histiozytose) dar [13, 52].  
Bei NBO sowie bei BO ist das Leitsymptom der lokale Schmerz, was eine besondere 
Herausforderung für die Diagnosestellung darstellt [19, 86]. Jedoch präsentieren sich Patienten 
mit einer NBO erfahrungsgemäß in einem guten Allgemeinzustand, mit multiplen 
Knochenherden, sind dabei meistens weiblich und haben ein Medianalter von 11 Jahren (SD: 3,2 
Jahre). Auf der anderen Seite sind Patienten mit einer BO häufig männlich, jünger und weisen 
vorwiegend unifokale Knochenläsionen sowie Fieber, hohe Entzündungszeichen und lokale 
Rötungen auf.  
Während ein Erregernachweis für eine BO spricht, jedoch nur in etwa der Hälfte der 
bakteriellen Infektionen nachgewiesen werden kann, handelt es sich bei einer NBO um eine 
Ausschlussdiagnose. Da keine standardisierten Diagnosekriterien für NBO existierten, war es das 
Ziel des ersten Teiles dieser Dissertation (ESPED-Studie) die Differenzierung zwischen NBO und 
BO zu verbessern und somit unnötige antibiotische Therapien zu vermeiden. Zeitgerechte 
Diagnosestellung und gezielte Behandlung reduzieren die Belastung der Patienten und des 
Gesundheits-Systems. Diese Studie ist die erste prospektive deutschlandweite Erhebung zur 
Erstmanifestation der NBO im Kindesalter und die erste prospektive deutschlandweite Erhebung 
zur Erstmanifestation der BO im Kindesalter. Über fünf Jahre wurden 279 Patienten mit NBO 
erfasst sowie über 2 Jahre 378 Patienten mit BO. Dies stellt zu diesem Zeitpunkt das größte 
publizierte Kollektiv von NBO Fällen dar.  
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Das Ziel der zweiten Untersuchung war es, ein besseres Verständnis der chronisch- 
nichtbakteriellen Osteitis (CNO) aus der Patientenperspektive zu erlangen. Dabei war es wichtig, 
in wie weit Betroffene über ihre Erkrankung informiert waren, die psychosoziale Auswirkung 
erfragt sowie Ansätze zur Verbesserung der Behandlung und Betreuung diskutiert wurden. An 
zwei Patienteninformationsveranstaltungen (2013 und 2015) waren insgesamt 107 Patienten 
anwesend, welche an unserer Erhebung teilnahmen. Die erhobenen Daten stellen die erste 
Untersuchung weltweit bezüglich der Auswirkung von CNO aus der Patientenperspektive dar.  
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